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OBJECTIVE — To examine the relationship between Zn nutritive status and biochemical
markers of bone turnover in type 1 diabetes.
RESEARCH DESIGN AND METHODS — Serum osteocalcin, urine N-telopeptides,
and dietary intake data, obtained by 3-day food records, were assessed for 66 individuals with
type 1 diabetes.
RESULTS — Zn intake correlated with osteocalcin in the group overall (r  0.48; P  0.001)
but not with N-telopeptides. Examined by sex, both Zn and osteocalcin correlated for men (r 
0.57; P  0.001), but the correlation did not reach statistical signiﬁcance for women (r 
0.34; P  0.09). A direct-entry linear regression model with osteocalcin as the dependent
variable was performed. Duration, sex, A1C, insulin use per kilogram, total calorie intake,
and Zn intake were entered as potential independent variables. The model was statistically
signiﬁcant(R
20.32;P0.01).Znintake(P0.001),however,wastheonlyindependent
correlate of osteocalcin.
CONCLUSIONS — This study provides evidence of a positive relationship between Zn
intake and osteocalcin in type 1 diabetes.
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Z
incisimportantinbonemetabolism
(1). Work in cell cultures and ani-
mal models have shown stimulation
ofosteoblastsbyZn(2),whileosteoclastic
cell formation was inhibited (3). Reduced
Zn levels associated with decreased bone
mineral content have been observed for
type 1 diabetic individuals (4). To our
knowledge, there have been no studies in
type 1 diabetes that examine Zn nutritive
status and biochemical markers of bone
turnover.
RESEARCH DESIGN AND
METHODS— Type 1 diabetic par-
ticipants (n  66; mean  SD age 42 
10 years) were evaluated in the Human
Performance Laboratory, University of
Delaware, Newark, Delaware. This
study had the approval of the institu-
tional review board of the University of
Delaware. Individuals with possible
secondary causes of osteoporosis (e.g.,
hyperparathyroidism) were excluded,
although seven did have borderline de-
creased vitamin D levels but normal
parathyroid hormone levels. Analysis of
the data omitting these subjects pro-
duced similar results; thus, they were
included in the study cohort.
Women who were in menopause
were excluded from participation. Meno-
pausal status was based on self-reported
frequency of menstrual cycles.
Participantsrecordedtheirdietaryin-
take for 3 days. Nutrient content was de-
termined with the Food Processor
Nutrition Analysis and Fitness software
package (version 8.0; ESHA Research,
Salem, OR).
Blood and urine samples were col-
lected in the morning following an over-
night fast. Serum osteocalcin was
measured via an immunoradiometric as-
say. Urine N-telopeptides were deter-
mined via a Vitros ECi competitive assay
on a morning spot sample.
Univariate analyses included Stu-
dent’s t test, the 
2 test, and Pearson cor-
relations. Linear regression was used to
assess potential independent associations
for markers of bone turnover (i.e., depen-
dent variable).
RESULTS— Biomarkers of bone turn-
over stratiﬁed by sex are presented in Ta-
ble 1. Participants consumed, on average,
slightly more Zn than the daily recom-
mendeddietaryallowance(RDA)(11mg/
day for men and 8 mg/day for women). It
should be noted, however, that approxi-
mately one-third of the individuals dem-
onstrated values less than the RDA.
Osteocalcin levels were lower for individ-
uals with Zn intake levels below the RDA
(15.9  5[ n  21] vs. 19.6  6 ng/ml
[n  45]; P  0.05).
Zn intake correlated with osteocal-
cin in the group overall (r  0.48; P 
0.001).Whenexaminedbysex,bothZn
intake and osteocalcin levels were
highlycorrelatedformen(r0.57;P
0.001), but the correlation did not
reach statistical signiﬁcance for women
(r  0.34; P  0.09). No signiﬁcant
correlations were observed for N-
telopeptides and Zn.
A direct-entry linear regression
model, with osteocalcin as the depen-
dent variable, was performed. With du-
ration of diabetes, sex, A1C, insulin use
per kilogram, total calorie intake, and
Zn entered as potential independent
variables, the overall model was signif-
icant (R
2  0.32; P  0.01). Zn intake
(P  0.001), however, was the only in-
dependent correlate of osteocalcin,
whereas sex was borderline statistically
signiﬁcant (P  0.061). A potential in-
teractionbetweensexandZnintakewas
investigated and found not to be signif-
icant. In sex-speciﬁc models, control-
ling for the other variables, Zn intake
(P  0.01) was independently associ-
ated with osteocalcin for men (R
2 
0.34 and P  0.05 for the model) but
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R
2 for the model when Mg, phosphorus
(P), or Ca was entered as a potential
independent variable replacing Zn. No
other micronutrient produced as strong
an R
2 for the regression model as that
for Zn, and only P was independently
associated with osteocalcin (P  0.05).
No independent association with Zn
was found when N-telopeptides were
used as the dependent variable.
CONCLUSIONS — This study indi-
cates that Zn intake is associated with a
marker of bone turnover. Although it
has been shown that Zn stimulates os-
teoblasts and the Zinc Effects on Nutri-
ent/nutrient Interactions and Trends in
Health and ageing (ZENITH) study (5)
showed some, albeit inconsistent, evi-
dence of a relationship between Zn nu-
tritive status and bone turnover, to our
knowledge this is the ﬁrst study in type
1 diabetes that shows an independent
association for Zn intake and osteocal-
cin. Our results, however, suggest that
this relationship may be stronger for
men than for women.
Zn plays several roles in bone me-
tabolism. Zn stimulates bone protein
synthesis and bone formation in tissue
cultures(2).TheanaboliceffectofIGF-I
in osteoblasts is enhanced by Zn (6). Zn
deﬁciency, however, impairs DNA syn-
thesis and protein metabolism, nega-
tively impacting bone formation (1). In
type 1 diabetic individuals with poor
glycemic control, Arreola et al. (4)
showed a signiﬁcant decrease in both
bone mineral content and Zn, suggest-
ing that Zn deﬁciency may be a contrib-
utory factor to bone loss. Some have
suggested that Zn deﬁciency leads to an
increase in free radical production (7).
Oxidative stress has been shown to be
an independent risk factor for osteopo-
rosis (8).
Why Zn intake appears to be more
strongly associated with osteocalcin for
men than for women is not clear. It may
be because the women in our study
were not in menopause. Herzberg et al.
(9) showed that urinary discharge of Zn
is increased in postmenopausal women
with osteoporosis. Thus, perhaps the
role of Zn in bone metabolism plays a
larger role for women once they have
reached menopause. It should be noted
that there was no signiﬁcant association
ofagewithmarkersofboneturnoverfor
either sex. No association between Zn
intake and N-telopeptides was noted.
Only one morning urine sample was
collectedforN-telopeptides,whichmay
explain the lack of association because
of a large intra-individual variability for
N-telopeptides.
This study provides evidence of a
relationship between Zn and a marker
of bone turnover in type 1 diabetes. As
for its limitations, the cross-sectional
nature of the study indicates associa-
tions, and causality remains to be clari-
ﬁed. Inaddition, for 9 of 25 subjects who
were taking a multivitamin, the exact Zn
content of their supplement could not be
determined. A common multivitamin
withanaverageZn,Ca,Mg,andPcontent
was assigned to these subjects. This as-
signment could have attenuated the asso-
ciations, potentially obscuring that
between N-telopeptides and Zn intake.
Multivariate analysis omitting these sub-
jects, however, produced similar results.
Although the importance of higher
levels of osteocalcin with regard to bone
health is not clear, dietary factors are
modiﬁable. Given that an inadequate in-
take of Zn has been reported as a risk fac-
tor for fractures in men (10), Zn may be
important in reducing this risk in people
with type 1 diabetes.
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Table 1—Bone biomarkers and Zn intake levels for the study cohort (n  66)
Men Women P
n 39 27 —
Osteocalcin (ng/ml) 19.9  5.5 16.2  5.8 0.05
N-telopeptides (nmol/mmol)* 31.2  12.8 25.1  10.3 0.05
Zn (mg) 15.8  9.0 14.2  7.1 NS
Subjects below the RDA for Zn intake per day 15 (38) 6 (22) NS
Data are means  SD or n (%) unless otherwise indicated. *Units of measurement for urine N-telopeptides
are nmol bone collagen equivalents/mmol creatinine. NS, nonsigniﬁcant.
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